Evaluating Remdesivir for treating Long COVID symptoms
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
This study is testing if the antiviral drug Remdesivir can help people with Long COVID feel better by reducing their ongoing symptoms.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Derby Academic / other |
| Locations | 4 sites (Chesterfield and 3 other locations) |
| Trial ID | NCT05911906 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the efficacy of Remdesivir, an antiviral medication, in patients suffering from Long COVID, a condition characterized by persistent symptoms following SARS-CoV-2 infection. Participants will undergo a series of tests to evaluate their symptoms and the impact of Long COVID on their health over an 8-week period, involving 13 visits to study locations in Derby or Exeter. The study seeks to determine whether Remdesivir can alleviate the symptoms associated with Long COVID, which currently lacks effective treatments.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of Long COVID following a SARS-CoV-2 infection.
Not a fit: Patients who have previously received treatment with Remdesivir or other specified antiviral medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients suffering from Long COVID.
How similar studies have performed: While the use of antiviral medications for Long COVID is a relatively novel approach, there is ongoing interest in their potential effectiveness, and this study could provide valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years of age at the time of enrolment * Previously confirmed or suspected SARS-CoV-2 infection * Confirmed diagnosis of Long COVID by a Health Care Practitioner according to the \*definition provided by the World Health Organisation for persistent symptoms following a confirmed SARS-CoV-2 infection. * Willing and able to provide informed consent, complete the surveys, and complete all planned clinical assessments, and return for scheduled study visits. * Evidence of persistent symptom profile relative to pre-COVID-19 status as derived from patient reported outcome measures. * Lives within commutable distance of the relevant centre, at discretion of local Principal Investigator. * WHO define Long COVID as the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation. Exclusion Criteria: * Treatment history of Remdesivir, molnupiravir, paxlovid and/or any other COVID-19 anti-viral medication (\<6 months). * A diagnosis of a compromised immune system or function from a Healthcare Professional. * Currently engaged in a physical rehabilitation programme or intervention aimed to improve Long COVID symptom profile and/or functional status. * Recognised as a 'severe risk' of experiencing post-exertional malaise following engagement in physical tasks. Determined using the Modified De Paul Symptom Questionnaire. * Lack of mental capacity to provide informed consent. * Unable to understand verbal English/have a hearing impairment that prevents adequate communication.\* * Participation in another clinical drugs trial within the last 6 months * Currently pregnant, breastfeeding or attempting to get pregnant (i.e., not using effective methods of contraception). * Currently taking medications known to have an interaction with Remdesivir (e.g., chloroquine phosphate or hydroxychloroquine) as defined by British National Formulary (BNF) information on the selection, prescribing, dispensing and administration of medicines: https://bnf.nice.org.uk/interactions/Remdesivir/ * History of serious adverse reactions to anti-viral medication and intravenous infusions * History of Hepatic or Renal Impairment (eGFR (\<30ml/min) and LFTs ALT\>x5 ULN). * Exeter participants only: No recent/long standing history of CT (within 3 months)/ ongoing radiotherapy treatment. Risks of accumulative burden to be discussed as part of study involvement but it is at the discretion of participants. \*Note: * English Comprehension: Potential participants who are unable to understand verbal English will not be eligible for this study. This is due to the necessity of telephone contact which is a key aspect of this study and the unavailability of validated questionnaires in languages other than English. * Hearing Impairment: Unfortunately, if the participant has a hearing impairment that prevents adequate communication on the telephone, they will not be able to take part in the study. This will be clearly stated in the participant information sheet.
Where this trial is running
Chesterfield and 3 other locations
- Derbyshire Community Health Services NHS Foundation Trust — Chesterfield, United Kingdom (Not_yet_recruiting)
- Royal Derby Hospital (UHDB) — Derby, United Kingdom (Not_yet_recruiting)
- University of Derby — Derby, United Kingdom (Recruiting)
- University of Exeter / Royal Devon University Healthcare NHS FT — Exeter, United Kingdom (Not_yet_recruiting)
Study contacts
- Study coordinator: Mark Faghy, PhD
- Email: m.faghy@derby.ac.uk
- Phone: 0133 259 2109
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.